To ensure that we are providing our clients with the industry's best and most current clinical information, we complete a "post-publication" process and receive feedback regarding opportunities to add additional information or, in rare cases, make revisions.

Below is information on revisions, corrections, or modifications to existing monographs that have been identified in the past 12 months.

Hepatitis A Vaccine – April 2022

Revision in the Dosing: Adult field of the Hepatitis A Vaccine monograph in the Lexi-Drugs and Drug Facts and Comparisons databases.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

0.5 mL (50 units)

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

0.5 mL (25 units)

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Gabapentin – March 2022

Revision in the Dosing: Adult field of the Gabapentin monograph in the Lexi-Drugs and Drug Facts and Comparisons databases, available online.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

300 mg once on day 1,300 mg

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

300 mg once on day one, 300 mg

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Nifedipine – March 2022

Revision in the Dosing: Adult field of the Nifedipine monograph in the Lexi-Drugs database, available online and in mobile apps.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

systolic BP ≥60 mm Hg

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

systolic BP ≥160 mm Hg

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Tobramycin (Systemic) – February 2022

Revision in the Dosing: Adult field of the Tobramycin (Systemic) monograph in the Lexi-Drugs and Drug Facts and Comparisons databases, available online.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

Continuous (with every exchange) (dose is per liter of dialysate):

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

Continuous (with every exchange):

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Enoxaparin – January 2022

Revision in the Dosing: Adult field of the Enoxaparin monograph in the Lexi-Drugs and Drug Facts and Comparisons databases, available online and in mobile apps.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

SUBQ: 20 mg started 2 to 4 hours before surgery and 40 mg once daily thereafter (ASCO [Key 2020]).

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

SUBQ: 40 mg started 2 to 4 hours before surgery and 40 mg once daily thereafter (ASCO [Key 2020]).

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Neostigmine – December 2021

Revision in the Maximum Dose field of the Neostigmine monograph in the Drug Facts and Comparisons database.

The monograph previously read:

Maximum Dose (only portion of field impacted is presented):

0.7 mg/kg or up to a total of 5 mg (whichever is less) for the reversal of effects of nondepolarizing neuromuscular blocking agents according to the prescribing information.

It has been revised to read:

Maximum Dose (only portion of field impacted is presented):

0.07 mg/kg or up to a total of 5 mg (whichever is less) for the reversal of effects of nondepolarizing neuromuscular blocking agents according to the prescribing information.

These changes have been automatically posted to the online database.

Sorafenib – October 2021

Revision in the Dosing: Adjustment for Toxicity: Adult field of the Sorafenib monograph in the Lexi-Drugs and Drug Facts and Comparisons databases.

The monograph previously read:

Dosing: Adjustment for Toxicity: Adult (only portion of field impacted is presented):

Alkaline phosphatase increase (any grade) in the absence of known bone pathology: Permanently discontinue sorafenib.

Bilirubin increase (grade 2 or higher): Permanently discontinue sorafenib.

It has been revised to read:

Dosing: Adjustment for Toxicity: Adult (only portion of field impacted is presented):

Alkaline phosphatase increase (any grade) in the absence of known bone pathology and bilirubin increase (grade 2 or higher): Permanently discontinue sorafenib.

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Binimetinib – October 2021

Revision in the Dosing: Adjustment for Toxicity: Adult field of the Binimetinib monograph in the Lexi-Drugs database, available online and in mobile apps.

the monograph previously read:

Dosing: Adjustment for Toxicity: Adult (only portion of field impacted is presented):

First dose reduction: 30 mg once twice daily

It has been revised to read:

Dosing: Adjustment for Toxicity: Adult (only portion of field impacted is presented):

First dose reduction: 30 mg twice daily

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Empagliflozin Oral – September 2021

Revision in the Dosing: Renal Function Impairment field of the Empagliflozin Oral monograph in the Drug Facts & Comparisons database, available online.

The monograph previously read:

Dosing: Renal Function Impairment (only portion of field impacted is presented):

Benefits of 10 mg once daily have been shown in patients with an eGFR <20 mL/minute/1.73 m2.

It has been revised to read:

Dosing: Renal Function Impairment (only portion of field impacted is presented):

Benefits of 10 mg once daily have been shown in patients with an eGFR 20 mL/minute/1.73 m2.

These changes have been automatically posted online.

Casirivimab and Imdevimab – September 2021

Revision in the Dosing: Adult field of the Casirivimab and Imdevimab monograph in the Lexi-Drugs and Drug Facts & Comparisons databases, available online and in mobile apps.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

IV, SUBQ: Weight ≥40 kg: Casirivimab 600 mg and imdevimab 600 mg as a single dose…

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

IV, SUBQ: Casirivimab 600 mg and imdevimab 600 mg as a single dose…

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Aminocaproic Acid – August 2021

Revision in the Contraindications field of the Aminocaproic Acid monograph in the Lexi-Drugs and Drug Facts and Comparisons databases.

The monograph previously read:

Contraindications (only portion of field impacted is presented):

Primary fibrinolysis or disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process

It has been revised to read:

Contraindications (only portion of field impacted is presented):

Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Cyclophosphamide – July 2021

Revision in the Dosing: Adult field of the Cyclophosphamide monograph in the Lexi-Drugs database, available online and in mobile apps.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

IV (high-dose therapy): 50 mg/kg/day (based on ideal body weight) on days 1 to 4 (in combination with mesna and G-CSF); RBC transfusion independence occurred at a median of 19 days (Moyo 2002) or 50 mg/kg/day on days 1 to 4 (in combination with mesna and G-CSF) (Go 2017) or 1,000 mg once a week for 4 doses (Go 2017).

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

IV (high-dose therapy): 50 mg/kg/day (based on ideal body weight) on days 1 to 4 (in combination with mesna and G-CSF); RBC transfusion independence occurred at a median of 19 days (Moyo 2002) or 50 mg/kg/day on days 1 to 4 (in combination with mesna and G-CSF) (Go 2017) or 1,000 mg once every 4 weeks for 4 doses (Go 2017).

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Larotrectinib – April 2021

Revision in the Dosing: Adult field of the Larotrectinib monograph in the Lexi-Drugs database, available online and in mobile apps.

The monograph previously read:

Dosing: Adult (only portion of field impacted is presented):

(content missing)

It has been revised to read:

Dosing: Adult (only portion of field impacted is presented):

Missed dose: Do not make up the missed dose within 6 hours of the next scheduled dose. If vomiting occurs, take the next dose at the scheduled time.

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Sacituzumab Govitecan – April 2021

Revision in the Dosing: Adjustment for Toxicity field of the Sacituzumab Govitecan monograph in the Lexi-Drugs and Drug Facts and Comparisons databases, available online and in mobile apps.

The monograph previously read:

Dosing: Adjustment for Toxicity (only portion of field impacted is presented):

(content missing)

It has been revised to read:

Dosing: Adjustment for Toxicity (only portion of field impacted is presented):

On day of scheduled sacituzumab govitecan dose, grade 3 or 4 non-neutropenic hematologic toxicity, which delays dosing by 2 or 3 weeks for recovery to ≤ grade 1

First

Reduce sacituzumab govitecan dose by 25%.

Second

Reduce sacituzumab govitecan dose by 50%.

Third

Discontinue sacituzumab govitecan.

These changes have been automatically posted to online and mobile app databases. Please update your mobile Lexi-Drugs application to get the updated monograph.

Back To Top